| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2013 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HARMONY BIOSCIENCES HLDGS IN | 13 | Q2 2024 | 21.3% |
| XENON PHARMACEUTICALS INC | 13 | Q2 2024 | 4.4% |
| BOLT BIOTHERAPEUTICS INC | 13 | Q2 2024 | 5.6% |
| KALVISTA PHARMACEUTICALS INC | 13 | Q2 2024 | 2.8% |
| EXELIXIS INC | 13 | Q2 2024 | 1.5% |
| ALX ONCOLOGY HLDGS INC | 13 | Q2 2024 | 1.0% |
| ILLUMINA INC | 12 | Q2 2024 | 21.5% |
| RANI THERAPEUTICS HLDGS INC | 12 | Q2 2024 | 3.5% |
| GALERA THERAPEUTICS INC | 12 | Q1 2024 | 1.9% |
| DBV TECHNOLOGIES S A | 12 | Q1 2024 | 0.6% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-13 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.